PMID- 40974872
OWN - NLM
STAT- Publisher
LR  - 20250920
IS  - 1872-8332 (Electronic)
IS  - 0169-5002 (Linking)
VI  - 208
DP  - 2025 Sep 16
TI  - Biological impact of chemotherapy during treatment with EGFR tyrosine kinase 
      inhibitors for non-small cell lung cancer positive for EGFR activating mutations.
PG  - 108756
LID - S0169-5002(25)00648-8 [pii]
LID - 10.1016/j.lungcan.2025.108756 [doi]
AB  - BACKGROUND: The aim of this study was to explore the biological impact of 
      chemotherapy during epidermal growth factor receptor (EGFR) tyrosine kinase 
      inhibitor (TKI) treatment in individuals with non-small cell lung cancer (NSCLC). 
      METHODS: Plasma and tumor tissue specimens were prospectively collected from 
      NSCLC patients with EGFR activating mutations who participated in a randomized 
      phase III study comparing EGFR-TKI therapy with or without inserted chemotherapy 
      (JCOG1404/WJOG8214L). The specimens were analyzed for genetic mutations by 
      droplet digital polymerase chain reaction analysis and next-generation 
      sequencing. RESULTS: Two hundred patients were enrolled in this biomarker study, 
      with 113 and 87 individuals receiving EGFR-TKI monotherapy and EGFR-TKI treatment 
      plus inserted chemotherapy, respectively. Although progression-free survival 
      (PFS) for EGFR-TKI monotherapy was shorter in patients with than in those without 
      detectable EGFR activating mutations in cell-free DNA at baseline, inserted 
      chemotherapy improved PFS compared with EGFR-TKI monotherapy for the former 
      patients (median, 17.5 vs. 11.8 months). Inserted chemotherapy suppressed the 
      number of alleles positive for activating and T790M mutations of EGFR in 
      cell-free DNA at disease progression. The benefit of inserted chemotherapy 
      relative to EGFR-TKI monotherapy was more apparent in patients with (median PFS, 
      18.8 vs. 13.5 months) than in those without detectable concurrent mutations of 
      TP53. CONCLUSIONS: Chemotherapy has the potential to suppress the development of 
      EGFR-TKI resistance as well as to inhibit tumor growth for NSCLC positive for 
      EGFR activating mutations. Our results provide biological insight into 
      combination treatment with EGFR-TKIs and chemotherapy for such patients.
CI  - Copyright © 2025 The Author(s). Published by Elsevier B.V. All rights reserved.
FAU - Iwama, Eiji
AU  - Iwama E
AD  - Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Sakai, Kazuko
AU  - Sakai K
AD  - Department of Genome Biology, Faculty of Medicine, Kindai University, 
      Osaka-Sayama, Japan.
FAU - Harada, Taishi
AU  - Harada T
AD  - Department of Respiratory Medicine, Japan Community Health Care 
      Organization-Kyushu Hospital, Fukuoka, Japan.
FAU - Kanda, Shintaro
AU  - Kanda S
AD  - Department of Hematology and Medical Oncology, Shinshu University School of 
      Medicine, Matsumoto, Japan; Department of Thoracic Oncology, National Cancer 
      Center Hospital, Tokyo, Japan.
FAU - Sugawara, Shunichi
AU  - Sugawara S
AD  - Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
FAU - Yokoyama, Toshihide
AU  - Yokoyama T
AD  - Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Japan.
FAU - Taniguchi, Hirokazu
AU  - Taniguchi H
AD  - Department of Respiratory Medicine, Nagasaki University Graduate School of 
      Biomedical Sciences, Nagasaki, Japan.
FAU - Tanaka, Kaoru
AU  - Tanaka K
AD  - Department of Medical Oncology, Kindai University Faculty of Medicine, 
      Osaka-Sayama, Japan.
FAU - Toyozawa, Ryo
AU  - Toyozawa R
AD  - Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan.
FAU - Koyama, Kenichi
AU  - Koyama K
AD  - Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan.
FAU - Zenke, Yoshitaka
AU  - Zenke Y
AD  - Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, 
      Japan.
FAU - Kida, Gen
AU  - Kida G
AD  - Department of Thoracic Oncology, Saitama Cancer Center, Saitama, Japan.
FAU - Nishioka, Yasuhiko
AU  - Nishioka Y
AD  - Department of Respiratory Medicine and Rheumatology, Graduate School of 
      Biomedical Sciences, Tokushima University, Tokushima, Japan.
FAU - Yokouchi, Hiroshi
AU  - Yokouchi H
AD  - Department of Respiratory Medicine, NHO Hokkaido Cancer Center, Sapporo, Japan.
FAU - Hirose, Masayuki
AU  - Hirose M
AD  - Center for Clinical and Translational Research, Kyushu University Hospital, 
      Fukuoka, Japan.
FAU - Nishio, Kazuto
AU  - Nishio K
AD  - Department of Genome Biology, Faculty of Medicine, Kindai University, 
      Osaka-Sayama, Japan.
FAU - Yamamoto, Nobuyuki
AU  - Yamamoto N
AD  - Internal Medicine III, Wakayama Medical University, Wakayama, Japan.
FAU - Ohe, Yuichiro
AU  - Ohe Y
AD  - Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
FAU - Okamoto, Isamu
AU  - Okamoto I
AD  - Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan. Electronic address: 
      okamoto.isamu.290@m.kyushu-u.ac.jp.
LA  - eng
PT  - Journal Article
DEP - 20250916
PL  - Ireland
TA  - Lung Cancer
JT  - Lung cancer (Amsterdam, Netherlands)
JID - 8800805
SB  - IM
OTO - NOTNLM
OT  - Chemotherapy
OT  - Circulating tumor DNA
OT  - Epidermal growth factor receptor (EGFR)
OT  - Osimertinib
OT  - Tyrosine kinase inhibitor
COIS- Declaration of competing interest The authors declare the following financial 
      interests/personal relationships which may be considered as potential competing 
      interests: Eiji Iwama has received honoraria from AstraZeneca K.K. and Chugai 
      Pharmaceutical. Kazuko Sakai has received honoraria from Qiagen, Inc., Takeda 
      Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd. and Life Technologies Japan 
      Ltd. Shintaro Kanda has received honoraria from AstraZeneca K.K., Bristol Myers 
      Squibb. K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai 
      Co., Ltd., Guardant Health AMEA, Kyowa Kirin Co., Ltd., MSD K.K., Nippon 
      Boehringer. Ingelheim Co., Ltd., Ono Pharmaceutical Co., Ltd., and Taiho 
      Pharmaceutical. Shunichi Sugawara has received honoraria from AstraZeneca K.K., 
      Amgen, Boehringer Ingelheim Co., Ltd., Bristol Myers Squibb K.K., Chugai 
      Pharmaceutical Co., Ltd., Eisai, Eli Lilly Japan K.K., Kyowa Kirin Co., Ltd., MSD 
      K.K., Merck, Novartis Pharma K.K, Nippon Kayaku Co., Ltd., Ono Pharmaceutical 
      Co., Ltd., Pfizer, Sysmex, Thermo Fisher Scientific, Takeda Pharmaceutical, and 
      Taiho Pharmaceutical. Toshihide Yokoyama has received honoraria from AbbVie GK, 
      AstraZeneca K.K., Boehringer Ingelheim Co., Ltd., Bristol Myers Squibb K.K., 
      Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Delta-Fly Pharma, 
      Janssen, MSD, Parexel International and Takeda Pharmaceutical. Kaoru Tanaka has 
      received honoraria from AstraZeneca K.K., Bristol Myers Squibb K.K., Chugai 
      Pharmaceutical Co., Ltd., Eisai, Merck Biopharma, MSD, Ono Pharmaceutical Co., 
      Ltd., Novartis Pharma, Taiho Pharmaceutical and Takeda Pharmaceutical. Ryo 
      Toyozawa has received honoraria from AstraZeneca K.K., Bristol Myers Squibb K.K., 
      Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., MSD K.K., Nippon Kayaku 
      Co.,Ltd., Ono Pharmaceutical Co., Ltd., Pfizer, Sysmex, Thermo Fisher Scientific, 
      Takeda Pharmaceutical, and Taiho Pharmaceutical. Yoshitaka Zenke has received 
      honoraria from Amgen Inc., AstraZeneca K.K., Bristol-Myers Squibb K.K., Chugai 
      Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Kyowa Kirin Co., Ltd., MSD K.K., 
      Nippon Boehringer Ingelheim Co., Ltd., Nippon Kayaku Co., Ltd., Novartis Pharma 
      K.K., Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc., Taiho Pharmaceutical Co., 
      Ltd., and Takeda Pharmaceuticals Co., Ltd., Guardant health, J&J Innovative 
      Medicine; grants or other funding from Amgen Inc., AstraZeneca K.K., Chugai 
      Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Merck Biopharma Co., Ltd., 
      MSD K.K., Novocure, GSK, and Nippon Boehringer Ingelheim Co., Ltd. K. Yasuhiko 
      Nishioka has received honoraria from AstraZeneca K.K. Hiroshi Yokouchi has 
      received honoraria from AstraZeneca K.K.and Chugai Pharmaceutical Co., Ltd; 
      research funding from AstraZeneca K.K., Amgen, AbbVie, Bristol Myers Squibb K.K., 
      Chugai Pharmaceutical Co., Ltd., Daiichi-Sankyo, MSD K.K., Sanofi, and Takeda 
      Pharmaceutical. Kazuto Nishio has received honoraria from AstraZeneca K.K., 
      Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo, Eli Lilly Japan K.K., Invitae 
      Japan, MSD K.K., Maruho, Nichirei, Novartis Pharma K.K., Ono Pharmaceutical Co., 
      Ltd., Guardant health, and Janssen Pharmaceutical; grants or other funding from 
      Nippon Boehringer Ingelheim Co., Ltd., West Japan Oncology Group, Nichirei 
      Biosciences Inc. Eli Lilly Japan, Hitachi, Sysmex, Otsuka Pharmaceutical, 
      Thoracic Oncology Research Group, Okayama University, SymBio Pharmaceuticals and 
      Japan Breast Cancer Research Group. N Yamamoto has honoraria from AbbVie G.K., 
      Amgen Inc., Accuray Japan K.K., AstraZeneca K.K., Bristol-Myers Squibb K.K., 
      Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., 
      Guardant Health AMEA, Janssen Pharmaceutical K.K., Kyorin Pharmaceutical Co., 
      Ltd., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Merck 
      Biopharma Co., Ltd., Miyarisan Pharmaceutical Co., Ltd., USACO Corporation, 
      Medical Review Co.,Ltd., KOWA COMPANY LTD. MSD K.K., Nippon Boehringer Ingelheim 
      Co., Ltd., Nippon Kayaku Co., Ltd., Kyowa Kirin Co., Ltd., ShiftZero K.K., 
      Novartis Pharma K.K., Pfizer Japan Inc., Taiho Pharmaceutical Co., Ltd., Takeda 
      Pharmaceuticals Co., Ltd., Terumo Corporation, and Tsumura & Co.; grants or other 
      funding from AstraZeneca K.K., Amgen Inc., DAIICHI SANKYO, INC., MSD, USACO 
      Corporation, Ono Pharmaceutical Co., Ltd., and NovartisJapan. Yuichiro Ohe has 
      received honoraria from AstraZeneca, Chugai, Eli Lilly, ONO, BMS, Boehringer 
      Ingelheim, Bayer, Pfizer, MSD, Taiho, Nippon Kayaku, Kyowa Hakko Kirin, Eisai, 
      Daiichi-Sankyo; grants or other funding from AstraZeneca, Chugai, Eli Lilly, 
      Kirin, Sumitomo, Pfizer, Taiho, Novartis, Takeda, Daiichi-Sankyo, Janssen, ONO, 
      BMS, Kyorin, Celltrion, Amgen, nippon Kayaku, Boehringer Ingelheim, AnHeart 
      Therapeutics Inc. PharmaMar. Isamu Okamoto has received honoraria from 
      AstraZeneca, Taiho Pharmaceutical, Boehringer Ingelheim, Ono Pharmaceutical, MSD, 
      Eli Lilly Japan K.K., Bristol-Myers Squibb, Novartis, Chugai Pharmaceutical, 
      Pfizer; grants or other funding from AstraZeneca, Taiho Pharmaceutical, 
      Boehringer Ingelheim, Ono Pharmaceutical, MSD, Eli Lilly Japan K.K., Astellas, 
      Bristol-Myers Squibb, Novartis, Chugai Pharmaceutical, Pfizer, AbbVie. Other 
      authors declare no potential conflicts of interest.
EDAT- 2025/09/21 00:29
MHDA- 2025/09/21 00:29
CRDT- 2025/09/20 18:09
PHST- 2025/07/05 00:00 [received]
PHST- 2025/08/20 00:00 [revised]
PHST- 2025/09/13 00:00 [accepted]
PHST- 2025/09/21 00:29 [medline]
PHST- 2025/09/21 00:29 [pubmed]
PHST- 2025/09/20 18:09 [entrez]
AID - S0169-5002(25)00648-8 [pii]
AID - 10.1016/j.lungcan.2025.108756 [doi]
PST - aheadofprint
SO  - Lung Cancer. 2025 Sep 16;208:108756. doi: 10.1016/j.lungcan.2025.108756.
